Immune-Checkpoint Inhibitors Combinations in Metastatic NSCLC: New Options on the Horizon?

The therapeutic targeting of the programmed death-1 (PD-1)/programmed death ligand-1 (PD-L1) axis marked a milestone in the treatment of non-small cell lung cancer (NSCLC), leading to unprecedented response duration and long-term survival for a relevant subgroup of patients affected by non-oncogene-...

Descripción completa

Detalles Bibliográficos
Autores principales: Passiglia, Francesco, Reale, Maria Lucia, Cetoretta, Valeria, Novello, Silvia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7872895/
https://www.ncbi.nlm.nih.gov/pubmed/33575224
http://dx.doi.org/10.2147/ITT.S253581

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7872895/
https://www.ncbi.nlm.nih.gov/pubmed/33575224
http://dx.doi.org/10.2147/ITT.S253581

Ejemplares similares